Active symptom control with or without chemotherapy for mesothelioma (MS-01)
The MS01 trial is a randomized Phase III study comparing active symptom control, the current standard of treatment or active symptom control plus 1 or 3 anti-cancer drugs in patients with malignant mesothelioma. The goal of the trial is to determine which treatment is better at controlling the symptoms of mesothelioma.
Eligibility requirements for this trial are as follows:
You are not eligible for this trial if:
Group 1 will receive active symptom control (painkillers, steroids, etc.). The treatment you receive will depend on your individual symptoms.
Group 2 will receive active symptom control plus MVP chemotherapy. This chemotherapy combines the drugs mitomycin C, vinblastine and cisplatin. You will be given chemotherapy every three weeks over a twelve week period.
Group 3 will receive active symptom control plus one chemotherapy drug, vinorelbine (Navelbine). You will be given one injection once a week for six weeks, then no treatment for two weeks, then one injection once a week for an additional six weeks.
If you are interested in participating in this trial, you should ask your doctor for more information on whether it may be suitable in your particular case.